128940.KO Hanmi Pharm Co Ltd
- Market cap
- KRW 5.90T
- P/E
- 24.8x
- P/B
- 3.73x
- ROE
- 18.3%
- Dividend yield
- 0.52%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 128940.KO undervalued?
Graham number128940.KO trades 102.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hanmi Pharm Co Ltd fundamental analysis
No fundamental analysis for Hanmi Pharm Co Ltd yet.
Hanmi Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), a…
Full company profileHanmi Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hanmi Pharm Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 883B | 917B | 1.02T | 1.11T | 1.08T | 1.20T | 1.33T | 1.49T | 1.50T | 1.55T | 1.72T |
| Gross Profit | 461B | 518B | 541B | 632B | 581B | 633B | 719B | 829B | 817B | 884B | 1.04T |
| Operating Income | 26.8B | 82.2B | 83.6B | 104B | 49.0B | 125B | 158B | 225B | 216B | 258B | 369B |
| EBITDA | - | 106B | 117B | 164B | 108B | 209B | 241B | 321B | 293B | 329B | 464B |
| Net Income | 23.3B | 60.4B | 24.9B | 52.1B | 12.0B | 67.0B | 82.8B | 146B | 121B | 170B | 258B |
| EPS | - | 5,125 | 2,113 | 4,426 | 1,017 | 5,477 | 6,648 | 11,523 | 9,567 | 13,372 | 20,315 |
| Balance Sheet | |||||||||||
| Total Assets | 1.60T | 1.66T | 1.69T | 1.91T | 1.88T | 1.94T | 1.92T | 1.90T | 2.02T | 2.14T | 2.33T |
| Total Liabilities | 862B | 869B | 902B | 1.09T | 1.05T | 1.01T | 915B | 798B | 780B | 715B | 745B |
| Shareholders' Equity | 659B | 712B | 703B | 724B | 730B | 803B | 872B | 955B | 1.08T | 1.25T | 1.40T |
| Cash & Short-term Investments | 130B | 47.3B | 67.3B | 106B | 146B | 209B | 147B | 55.0B | 192B | 108B | 209B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 413B | -62.9B | 26.0B | 12.4B | 152B | 202B | 162B | 217B | 193B | 173B | 433B |
| Capital Expenditure | 224B | 247B | 182B | 166B | 41.8B | 19.9B | 30.4B | 43.7B | 62.6B | 76.5B | 93.8B |
| Free Cash Flow | - | -325B | -185B | -166B | 93.7B | 167B | 113B | 173B | 131B | 96.5B | 339B |
| Ratios | |||||||||||
| ROE | 3.5% | 8.5% | 3.5% | 7.2% | 1.6% | 8.3% | 9.5% | 15.3% | 11.2% | 13.6% | 18.3% |
| ROA | 1.5% | 3.6% | 1.5% | 2.7% | 0.6% | 3.5% | 4.3% | 7.7% | 6.0% | 7.9% | 11.0% |
| Net Profit Margin | 2.6% | 6.6% | 2.5% | 4.7% | 1.1% | 5.6% | 6.2% | 9.8% | 8.1% | 11.0% | 15.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hanmi Pharm Co Ltd dividends
- Dividend yield
- 0.52%
- Forward dividend
- 2,000.00 KRW
- Payout ratio
- 18.2%
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 30.9B | 2,433 | 18.2% |
| 2024 | KRW 12.6B | 990 | 10.3% |
| 2023 | KRW 18.0B | 1,418 | 12.3% |
| 2022 | KRW 5.99B | 481 | 7.2% |
| 2021 | KRW 5.88B | 481 | 8.8% |
| 2020 | KRW 8.14B | 692 | 68.1% |
| 2019 | KRW 5.66B | 481 | 10.9% |
| 2018 | KRW 8.96B | 760 | 36.0% |
| 2017 | KRW 8.96B | 760 | 14.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.02:1 on Dec 27, 2023.
Who owns Hanmi Pharm Co Ltd
- Insiders 49.58%
- Institutions 20.45%
- Public & others 29.97%
- Shares outstanding 12.7M
- Free float 6.34M
Hanmi Pharm Co Ltd company profile
- Company name
- Hanmi Pharm Co Ltd
- Ticker
- 128940.KO
- ISIN
- KR7128940004
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,336
- Fiscal year end
- December
- Address
- 214 Muha-ro, Hwaseong-si, South Korea, 18536
- Phone
- 82 3 1350 5600
- Website
- hanmipharm.com
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
Hanmi Pharm Co Ltd management
8- Mr. Jae-Hyun ParkCEO & Director · born 1968
- Mr. Lim Chong-YoonPresident of Business Development & Executive Director · born 1972
- Mr. Jong-Hoon LimCSR Executive Director · born 1961
- Byung-hwa ShimChief Finance Officer
- Yang-Hwan ChoiGroup Head of IR
- Mr. Jong-Soo Woo Ph.D.Executive Director · born 1967
- Mr. Jong-Hoon LimExecutive Director & Management Planning /CIO · born 1977
- Chang-Ju ChoiVice President of Information Management Team